Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Free Cash Flow for 9 consecutive years, with -$100.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 12.67% to -$100.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$422.1 million through Dec 2025, down 16.09% year-over-year, with the annual reading at -$422.1 million for FY2025, 16.09% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$100.1 million at Denali Therapeutics, up from -$105.9 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$43.1 million in Q2 2022, with the low at -$132.0 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$81.1 million, with a median of -$79.0 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 3838.14% in 2021, then skyrocketed 35.36% in 2024.
  • Over 5 years, Free Cash Flow stood at -$68.5 million in 2021, then decreased by 7.73% to -$73.8 million in 2022, then crashed by 36.63% to -$100.9 million in 2023, then rose by 11.98% to -$88.8 million in 2024, then dropped by 12.67% to -$100.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$100.1 million, -$105.9 million, and -$84.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.